Droperidol Reduces Postoperative Nausea and Vomiting and Supports the Continuation of Intravenous Patient-Controlled Analgesia with Fentanyl

Ikkou Hirata a, Masahiro Iwamoto a, Hiroki Matsui b, Hiromi Yoshinuma c, Ryohkan Funakoshi a

a Department of Pharmacy, Kameda General Hospital, Chiba, Japan. b Clinical Research Unit, Kameda Medical Hospital/Kameda College of Health Science, Chiba, Japan. c Department of Anesthesiology, Kameda General Hospital, Chiba, Japan.

Received, January 22, 2020; Revised, May 2, 2020; Accepted, June 16, 2020; Published, June 17, 2020

ABSTRACT- PURPOSE: To examine the impact of adding droperidol to fentanyl-based intravenous patient-controlled analgesia (IVPCA) on the discontinuation of IVPCA use due to postoperative nausea and vomiting (PONV).

METHODS: Patients who underwent surgeries other than abdominal surgeries and used IVPCA between April 2014 and March 2018 were selected. Patients using IVPCA with fentanyl alone were compared to patients using droperidol added to IVPCA. Patients were allocated to one of two groups depending on the drug used for IVPCA: 1) control group, fentanyl alone; 2) droperidol group, droperidol with fentanyl. The primary endpoint was the discontinuation of IVPCA due to PONV. Secondary endpoints included PONV within 48 hours after surgery, the number of antiemetics used, pain score, and adverse effects. Propensity score matching was used to control the differences in clinical features among patients. RESULTS: Among the 793 patients initially enrolled in this study, 145 were excluded via propensity score matching; 364 of the remaining patients received IVPCA supplemented with droperidol. Propensity score matching showed that discontinuation of IVPCA due to PONV was significantly decreased in the droperidol group compared to the control group (P = 0.01). Further, compared with the control group, the droperidol group had reduced nausea up to 24 hours after surgery (P < 0.01), and the number of vomiting episodes and use of antiemetics decreased within 12 hours after surgery (P < 0.01).

CONCLUSIONS: The addition of droperidol to IVPCA is associated with a decrease in PONV, as well as the improved continuation of pain treatment with fentanyl-based IVPCA, similar to IVPCA with morphine. However, it is necessary to monitor the side effects of this treatment.

KEYWORDS: Droperidol, Postoperative nausea and vomiting, Intravenous patient-controlled analgesia, Postoperative pain

INTRODUCTION

After surgery, many patients experience postoperative pain, as well as postoperative nausea and vomiting (PONV). Intravenous patient-controlled analgesia (IVPCA) with fentanyl is widely used to decrease postoperative pain. However, anesthetic-induced PONV and opioids used for IVPCA often lead to the discontinuation of IVPCA, which compromises postoperative pain management and increases medical care costs (1-5). Commonly used antiemetics include 5-hydroxytryptamine-3 receptor antagonists (5HT3RA) and neurokinin-1 receptor antagonists (NK1RA), which have been shown to combat PONV effectively. However, unpleasant side effects, medical care costs, and off-label usages have been noted with these drugs, which significantly limits available therapeutic options for these patients. Despite droperidol being the most cost-effective antiemetic alternative, its usage has decreased due to a warning of fatal arrhythmia by the Food and Drug Administration (6-8). In this study, the addition of droperidol to IVPCA reduced PONV and IVPCA discontinuation. Although droperidol has been widely used for a few decades, real-world reports of its use are inadequate, and its efficacy and safety when added to fentanyl are unclear (9-13). Therefore, in this retrospective study, we investigated the impact of adding droperidol to fentanyl-based IVPCA on the discontinuation of IVPCA due to PONV.

MATERIALS AND METHODS

This retrospective cohort study was carried out within
a single facility, from which we collected information from patients’ medical records following validation by two people.

This study complied with the standards of the Declaration of Helsinki and the current ethical guidelines. The design and methodology, including the opt-out method of consent available to all patients, was approved by the Kameda General Hospital Clinical Research Review Committee (Approval number: 18–073) and adhered to the applicable STROBE guidelines.

**Study Population**

Patients who underwent surgeries other than abdominal surgeries and received IVPCA between April 2014 and March 2018 were retrospectively enrolled. Patients were allocated to one of two groups depending on the drug used for IVPCA: 1) control group, fentanyl alone; 2) droperidol group, droperidol with fentanyl. Patients were excluded if they met the following criteria: 1) had Alzheimer’s disease or were using antidementia drugs before surgery; 2) had difficulty understanding the numerical rating scale (NRS); or 3) had a poor understanding of the IVPCA education provided by the pharmacist.

**Anesthesia Method and IVPCA Education**

From the clinical records, we recorded the method and type of anesthesia, analgesics, and prophylactic antiemetics administered during surgery by an anesthesiologist. In Japan, medical care is covered by the National Health Insurance System, and by policy, the clinical use of certain drugs is not permitted. We were unable to use the expensive 5HT3RA and NK1RA for PONV. Therefore, anesthesiologists provided one or more prophylactic antiemetics, such as dexamethasone, droperidol, prochlorperazine, and metoclopramide to patients with PONV risk ≥2 as a routine treatment. None of the patients received premedication. IVPCA was initiated immediately before the end of surgery with a Coopdech® Syringejector® PCA mobile disposable infusion pump (Daiken Medical Corporation, Osaka, Japan). The IVPCA comprised of a solution containing 40 mL of 0.9% physiological saline and 1 mg of fentanyl citrate (0.5 mg/10 mL), to which 2.5 mg of droperidol was added per 60 mL of solution. Surgeons were given discretion on whether to add droperidol to the IVPCA. The continuous infusion rate was usually fixed at 1.0mL/h. However, the surgeon could change it to 0, 0.5, 1, or 1.5mL/h depending on the pain and side effects; the rescue dose was set as 1 mL, the lockout time was 10 min, and 6 rescue doses were allowed per hour. During the abstraction period, the policy of our hospital was to use prochlorperazine first and metoclopramide afterward. The selection and administration rate of drugs postoperatively, including droperidol or an antiemetic, was determined at the surgeon’s discretion. Physicians continued treatment with IVPCA until patients completed the prescribed course or experienced no pain. If the patients revealed symptoms of severe PONV, side effects, or device errors, the use of IVPCA was discontinued. The use of the disposable IVPCA device was not resumed after discontinuation due to these reasons.

Per the standard protocol, all patients received information about anesthesia and IVPCA from the anesthesiologist before their surgery. Patients undergoing scheduled surgery received standardized education by pharmacists trained in the use of IVPCA, which was conducted at the patient's bedside and included instructions on the use of IVPCA, the effects and side effects of the medication, and the use of additional analgesics and antiemetics. The pharmacist assessed the patients’ depth of understanding and asked them to demonstrate their capability to press the rescue button on the device. Patients who required urgent IVPCA after emergency surgery received a similar education from the pharmacist within 24 hours post-surgery. These evaluations were obtained from available medical records.

**Endpoints**

Patients using IVPCA with fentanyl alone were compared to those using IVPCA with droperidol. The primary endpoint was the discontinuation of IVPCA use due to PONV, as described in the medical records. Secondary endpoints included PONV, the number of antiemetic agents used, pain score, and adverse effects within 48 hours after surgery. The adverse events investigated were drowsiness, delirium, dizziness, hypotension, extrapyramidal disorder, restlesslessness, and arrhythmias. Age and operation time were categorized based on PONV risk according to a consensus guideline, and body mass index (BMI) was categorized based on the World Health Organization classification. The reasons for IVPCA discontinuation were obtained from the medical records (1). Pain scores according to the NRS (rating 0–10) were evaluated at rest in the morning, afternoon, and evening by a nurse trained in pain evaluation. These scores were also obtained from the medical records.

**STATISTICAL ANALYSIS**

The Fisher's exact test was used for the analysis of categorical data, and the Mann-Whitney’s U test was used for the analysis of continuous variables. Targeting the available population, missing data were addressed by a full analysis of all cases. Propensity
score matching was carried out to control for any differences in clinical features between patients receiving IVPCA with and without added droperidol. These propensity scores were based on sex, age, BMI, the American Society of Anesthesiologists physical status (ASA-PS), history of PONV or motion sickness, smoking history in the past month before surgery, anesthesia method, operation time, number of PONV preventive drugs used, and pre-operative education by pharmacists. Patients with or without droperidol were matched 1:1 based on propensity scores and were not replaced. The matching caliper was set to a 20% standardized difference. This matching was confirmed using the standardized mean difference (SMD). To eliminate residual confounding factors in the groups after matching, all variables were entered into a generalized linear model, and dual-robust estimations were performed. All data were analyzed by a statistician using R (version 3.4.1). The significance level was set at $P < 0.05$.

RESULTS

During the study period, 793 patients underwent surgeries other than abdominal surgeries with IVPCA at our institution. Of these patients, 145 were excluded based on the exclusion criteria outlined above. Of the remaining 648 patients, general anesthesia was induced with propofol (an opioid) and a muscle relaxant and was maintained with desflurane or sevoflurane. Of the remaining 648 patients, 364 (56.2%) received IVPCA with droperidol (Figure 1).

The droperidol group had lower ASA-PS ($P = 0.02$), more motion sickness ($P = 0.02$), different types of surgery ($P < 0.001$), shorter surgery time ($P < 0.001$), shorter anesthesia time ($P < 0.001$), and received more preventive antiemetics ($P = 0.04$) than the control group. Even after propensity score matching, the SMD was more than 10% for surgery type and anesthetic method (Table 1).

The discontinuation of IVPCA due to PONV was significantly decreased in the droperidol group ($P = 0.01$) compared to the control group. In addition, discontinuation of IVPCA due to the absence of pain was increased in the droperidol group compared to the control group (Table 2). No patients deviated from the standard response in the prevention and treatment of PONV.

![Flowchart of the study population](image)

**Figure 1.** Flowchart of the study population. This figure depicts the study selection process, illustrating the proportion of patients included, as well as the proportion excluded along with the deciding criteria. IVPCA, intravenous patient-controlled analgesia.
|                                | Before propensity score matching | After propensity score matching |
|--------------------------------|----------------------------------|---------------------------------|
|                                | Control  | Droperidol | Count | %     | Count | %     | P-value | SMD  | Count | %     | Count | %     | P-value | SMD  |
| Sex (female)                   |          |            |       |       |       |       |         |       |       |       |       |       |         |       |
|                                | Control  | Droperidol |       |       |       |       |         |       |       |       |       |       |         |       |
| Age (average ± SD), years      | 58.9     | 19.0       | 56.9  | 18.1  | 0.18  | 58.9  | 19.0    | 56.9  | 18.1  | 0.17  |       |         |       |
|                                |          |            |       |       |       |       |         |       |       |       |       |       |         |       |
| < 50 years                     |          |            | 24.1  | 4.4   | 0.54  | 24.1  | 4.4     | 24.3  | 3.9   | 0.54  |       |         |       |
| Body mass index (average ± SD), kg/m$^2$ |          |            | 21    | 7.4   | 0.07  | 21    | 7.4      | 24    | 3.9   | 0.07  |       |         |       |
|                                |          |            |       |       |       |       |         |       |       |       |       |       |         |       |
| < 18.5 kg/m$^2$                |          |            | 169   | 59.5  | 167   | 60.3  |         |       |       |       |       |       |         |       |
| 18.5–25.0 kg/m$^2$             |          |            | 94    | 33.1  | 92    | 35.5  |         |       |       |       |       |       |         |       |
| > 25 kg/m$^2$                  |          |            |       |       |       |       |         |       |       |       |       |       |         |       |
| ASA physical status            |          |            |       |       |       |       |         |       |       |       |       |       |         |       |
| 1                              | 53       | 18.7       | 100   | 27.4  | 0.02  | 23    | 0.23    | 53    | 20.2  | 0.21  | 0.16  |         |       |
| 2                              | 196      | 69.0       | 234   | 64.1  |       | 180   | 68.7    | 167   | 63.7  |       |       |         |       |
| 3                              | 35       | 12.3       | 31    | 8.5   |       | 29    | 11.1    | 25    | 9.5   |       |       |         |       |
| PONV history                   |          |            | 16    | 5.6   | 0.55  | 0.06  | 16      | 6.1   | 15    | 5.7   | 1.00  | 0.02  |         |       |
| Smoking history within 1 month |          |            | 44    | 15.5  | 0.90  | 0.02  | 41      | 15.6  | 44    | 16.8  | 0.81  | 0.03  |         |       |
| Motion sickness                |          |            | 39    | 13.7  | 0.02  | 0.20  | 38      | 14.5  | 38    | 14.5  | 1.00  | < 0.001 |         |       |
| Pre-operative education by pharmacists |          |            | 278   | 97.9  | 0.23  | 0.12  | 256     | 97.7  | 256   | 97.7  | 1.00  | < 0.001 |         |       |
| Surgery type                   |          |            |       |       |       |       |         |       |       |       |       |       |         |       |
| Spinal                         | 178      | 62.7       | 158   | 43.3  | < 0.001 | 1.04 |         |       |       |       |       |       |         |       |

Table 1. Patient characteristics.
| Description of prophylactic antiemetics taken by patients | 0 | 1 | 2 | 3 |
|----------------------------------------------------------|---|---|---|---|
| Dexamethasone                                            | 72| 57.0| 102| 28.0| 0.48| 0.06| 72| 27.5| 62| 23.7| 0.37| 0.09|
| Prochlorperazine                                          | 34| 12.0| 61| 16.8| 0.09| 0.14| 33| 12.6| 40| 15.3| 0.53| 0.07|
| Droperidol                                               | 30| 10.6| 59| 16.2| 0.04| 0.17| 30| 11.5| 37| 14.1| 0.43| 0.09|
| Metoclopramide                                           | 13| 4.6| 22| 6.0| 0.49| 0.07| 13| 5.0| 14| 5.3| 1.00| 0.02|

SMD, standardized mean difference; PONV, postoperative nausea and vomiting; SD, standard deviation; ASA, American Society of Anesthesiologists; TIVA, total intravenous anesthesia; iv, intravenously. Data are shown as count and % unless otherwise indicated. *Other surgeries include formation and breast surgery. **Prophylactic antiemetic drug is droperidol 0.625–1.25 mg iv, or prochlorperazine maleate 5 mg iv, or metoclopramide 10 mg iv.
Table 2. Reasons for discontinuation of intravenous patient-controlled analgesia.

|           | Control  | Droperidol |   | P-value |
|-----------|----------|------------|---|---------|
|           | (n = 262)| (n = 262)  |   |         |
| Count     | %        | Count      | % |         |
| Total     | 56       | 21.4       | 44| 16.8    | 0.18 |
| PONV      | 50       | 19.1       | 29| 11.1    | 0.01 |
| Side effect| 5        | 1.9        | 11| 4.2     | 0.20 |
| Device error | 0        | 0.0        | 3 | 1.1     | 0.15 |
| Other     | 1        | 0.4        | 1 | 0.4     | 1.00 |

PONV, postoperative nausea and vomiting.

After eliminating major residual confounders using dual-robust estimation, the addition of droperidol to IVPCA was found to significantly decrease PONV-related discontinuation of IVPCA (P = 0.01) (Table 3). A complete dosage of IVPCA was administered in 218 (83.2%) patients in the droperidol group and 206 (78.6%) patients in the control group (p = 0.18). Of the complete dosage patients, 24 (9.1%) in the droperidol group and 11 (4.2%) in the control group discontinued IVPCA due to the disappearance of pain (p = 0.04). Among patients who discontinued IVPCA (except for those with no pain), 24 (42.9%) in the control group and 11 (25.0%) in the droperidol group showed an increase in the NRS score by 2 or more points after discontinuation.

Table 3 Doubly robust estimator.

|                          | Odds ratio | 95% Confidence interval | P-value |
|--------------------------|------------|-------------------------|---------|
| Intercept                | 0.570      | 0.045 – 7.250           | 0.67    |
| Sex (female)             | 2.340      | 1.340 – 4.090           | <0.01   |
| Age < 50 years           | 1.060      | 0.509 – 2.220           | 0.87    |
| Body mass index          | 0.808      | 0.499 – 1.310           | 0.39    |
| ASA physical status      | 0.622      | 0.369 – 1.050           | 0.07    |
| PONV history             | 1.270      | 0.466 – 3.440           | 0.64    |
| Smoking history within 1 month | 0.199   | 0.060 – 0.665           | 0.01    |
| Motion sickness          | 1.700      | 0.882 – 3.290           | 0.11    |
| Pre-operative education by pharmacists | 1.340   | 0.246 – 7.260           | 0.74    |
| Surgery type             | 0.846      | 0.585 – 1.220           | 0.37    |
| Anesthesia method        | 1.810      | 0.962 – 3.400           | 0.07    |
| Surgery time > 1.47 h    | 0.985      | 0.382 – 2.540           | 0.98    |
| Number of prophylactic antiemetic drugs | 0.635   | 0.427 – 0.944           | 0.02    |
| Addition of droperidol   | 0.507      | 0.303 – 0.847           | 0.01    |

PONV, postoperative nausea and vomiting; ASA, American Society of Anesthesiologists.
Concerning secondary endpoints, the droperidol group reported decreased nausea up to 24 hours after surgery compared to the control group \((P < 0.01)\). Furthermore, the number of vomiting episodes and the number of times antiemetic drugs required were reduced up to 12 hours after surgery in the droperidol group compared to the control group \((P < 0.01)\) (Table 4).

Adverse effects, including drowsiness and extrapyramidal disorder, increased in the droperidol group, although there were no statistically significant differences between the groups in this respect (Table 4). The patients in the droperidol group had higher IVPCA rescue dose use (14 times [7–25] versus [vs.] 13 times [6–23]) \((P = 0.127)\) and a longer period of use (38 h [24–48] vs. 30 h [21–42]) than the control group \((P < 0.001)\). The pain scores were lower at all times in the droperidol group than in the control group. On the evening of the second day after surgery, the pain score was significantly different from that during the evening of the first day after surgery (Figure 2).

**DISCUSSION**

In this study, we evaluated the effectiveness and safety of adding droperidol to IVPCA with fentanyl on patients’ discontinuation of IVPCA due to PONV using a propensity score matching-based analysis. Adding droperidol to IVPCA with fentanyl was newly shown to decrease IVPCA discontinuation, improve continuation of pain treatment, and decrease PONV and postoperative pain.

In a previous study, discontinuation of IVPCA due to PONV was reported to be 14%, which was close to the value obtained in the present study (3). Additionally, earlier research has shown that adding droperidol to IVPCA containing morphine was effective against PONV for a limited time (9-13). However, in this study, adding droperidol was effective for up to 24 hours immediately after surgery.

We believe that previous studies did not adequately verify the influence of the preventive antiemetic agents used. In this investigation, we adjusted for the anesthesia method, preventive antiemetic drugs, and PONV risk by propensity score matching; thus, we showed that adding droperidol to IVPCA is effective for managing PONV. Droperidol has been reported to reduce PONV in a dose-dependent manner (11, 14), and its repeated use during droperidol-supplemented IVPCA can be expected to decrease PONV caused by anesthesia and opioids (9-13).

Lack of education and PONV has been reported to prevent the use of IVPCA (15, 16). The reduction of pain within our study can be explained by the decrease in PONV, which elevated the number of times IVPCA rescue doses were required and prolonged the period of IVPCA use. Therefore, in the droperidol group, the number of cases with discontinuation of IVPCA due to the absence of pain was increased.

**Figure 2.** The impact of droperidol on post-surgical pain. The boxes show the changes in the postoperative numerical rating scale (NRS) over time. Cyan indicates the fentanyl-alone control group, and red indicates the droperidol group. POD, postoperative day. *: \(P < 0.01\); **: \(P < 0.001\).
### Table 4 Outcomes

|                          | Control (n = 262) | Droperidol (n = 262) | P value |
|--------------------------|-------------------|----------------------|---------|
|                          | Count             | %                    | Count   | %      |        |
| PONV                     | 128               | 48.9                 | 82      | 31.3   | < 0.001|
| Time to end of PONV (average ± SD), h | 13.1             | 16.6                 | 7.97    | 14.0   | < 0.001|
| Nausea                   |                   |                      |         |        |         |
| < 12 h                   | 89                | 34.0                 | 50      | 19.1   | < 0.001|
| 12–24 h                  | 88                | 33.6                 | 50      | 19.1   | 0.001  |
| 24–48 h                  | 32                | 12.2                 | 19      | 7.3    | 0.08   |
| Total number of vomiting episodes |                   |                      |         |        |         |
| Total times, 1/2/3/4/5 times | 47/16/2/6/0       | 17.9/6.1/0.8/2.3/0   | 28/11/1/1/1 | 10.7/4.2/0.4/0.4/0.4 | 0.01   |
| < 12 h                   | 40                | 15.3                 | 20      | 7.6    | 0.01   |
| 12–24 h                  | 38                | 14.5                 | 25      | 9.5    | 0.11   |
| 24–48 h                  | 9                 | 3.4                  | 1       | 0.4    | 0.03   |
| Total antiemetic drugs of the treatments after the surgery$^a$ |                   |                      |         |        |         |
| Total times, 1/2/3/4/5/6/7 times | 58/22/3/3/2/1/1   | 22.1/8.4/1.1/1.1/0.8/0.4/0.4 | 32/11/5/0/2/0/2 | 12.2/4.2/1.9/0.0/0.0/0.8/0.0 | 0.002  |
| < 12 h                   | 66                | 25.2                 | 34      | 13.0   | 0.001  |
| 12–24 h                  | 40                | 15.3                 | 25      | 9.5    | 0.06   |
| Time   | Count | Rate | Count | Rate | p-Value |
|--------|-------|------|-------|------|---------|
| 24-48 h| 14    | 5.3  | 6     | 2.3  | 0.11    |

Description of the antiemetics received by the patients after surgery

| Antiemetic                  | Count | Rate | Count | Rate | p-Value |
|-----------------------------|-------|------|-------|------|---------|
| Prochlorperazine            | 84    | 32.1 | 43    | 16.4 | < 0.001 |
| Metoclopramide              | 24    | 9.2  | 14    | 5.3  | 0.13    |
| Total of common adverse events| 41    | 15.6 | 51    | 19.5 | 0.30    |
| Drowsiness                  | 18    | 6.9  | 32    | 12.2 | 0.05    |
| Delirium                    | 9     | 3.4  | 8     | 3.1  | 1.00    |
| Dizziness                   | 9     | 3.4  | 6     | 2.3  | 0.60    |
| Hypotension                 | 5     | 1.9  | 4     | 1.5  | 1.00    |
| Extrapyramidal disorder     | 1     | 0.4  | 4     | 1.5  | 0.37    |
| Restlessness                | 0     | 0.0  | 1     | 0.4  | 1.00    |
| Arrhythmia\(^\text{b}\)     | 1     | 0.4  | 0     | 0.0  | 1.00    |
| Other                       | 0     | 0.0  | 2     | 0.8  | 0.50    |

PONV, postoperative nausea and vomiting; SD, standard deviation; iv, intravenously.

\(^a\)Antiemetic drug is prochlorperazine maleate 5 mg iv or metoclopramide 10 mg iv.

\(^b\)Arrhythmias that required treatment.
Adverse events associated with droperidol have been reported in a systematic review; they include drowsiness (12–40% of cases) and extrapyramidal disorders (0.2% of cases) (17). In addition, several studies in which droperidol was added to morphine-based IVPCA showed that drowsiness was increased in the droperidol group (10-13). In this study, adverse effects associated with droperidol included drowsiness and extrapyramidal disorders, as mentioned above, which caused discontinuation of IVPCA in some cases. The increased rate of these adverse effects can be explained by the pharmacological action of droperidol (17). Patients with extrapyramidal disorders in the droperidol group did not use any medications other than droperidol. The symptoms of patients with suspected extrapyramidal disorders were improved by the discontinuation of IVPCA.

On December 5, 2001, the Food and Drug Administration issued a warning about an association between fatal arrhythmias and the use of droperidol (6). In subsequent studies, low doses of droperidol were not associated with increased arrhythmias and could be used safely (18-20). Nevertheless, the use of droperidol declined, and its effects were not studied further. In recent years, 5HT3RA and NK1RA have been widely used instead of droperidol and are recommended in the PONV consensus guidelines (1). However, 5HT3RA and NK1RA are expensive, while droperidol is an inexpensive and useful antiemetic agent in areas with medical resource and system limitations, as well as economic limitations.

Major causes of distress in surgical patients include postoperative pain and PONV, both of which require care (1, 21). However, it has been reported that the management of PONV remains insufficient (22). Not only do drug effectiveness and safety affect the disparity in measures for managing PONV, but cost and availability may also be important factors. Our study showed that adding droperidol to the pain management of fentanyl-based IVPCA could be a satisfactory approach for PONV care.

The study was limited in that it only included patients who underwent surgeries (other than abdominal surgeries); thus, the findings may not be generalizable to patients who undergo body cavity surgery. Second, since this was a retrospective study from a single facility, the treatments, including anesthesia, could not be standardized. Furthermore, a selection bias may exist due to the exclusion of certain patients. In this study, we performed propensity score matching, but we were unable to perform adequate adjustments for the surgical procedures and the anesthesia method. Hence, we performed dual-robust estimations, adjusting for residual confounding factors and obtained similar results. Third, common drugs for PONV like 5HT3RA and NK1RA could not be evaluated.

One of the strengths of this study was that it evaluated the effect of droperidol using propensity score matching to adjust for risk factors of PONV, such as a history of PONV or motion sickness, and the use of prophylactic antiemetic drugs during surgery.

In conclusion, the addition of droperidol to IVPCA is associated with a decrease in PONV, as well as an improved continuation of pain treatment with fentanyl-based IVPCA, similar to IVPCA with morphine. However, it is necessary to monitor the side effects of this treatment.

ACKNOWLEDGMENTS

We would like to express our gratitude to the project team members and pharmacists who provided patient education. We did not receive funding for this study.

CONFLICT OF INTEREST

The authors declare no conflict of interest associated with this manuscript.

REFERENCES

1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg, 2014; 118:85-113. doi: 10.1213/ANE.0000000000000002.

2. Cao X, White PF, Ma H. An update on the management of postoperative nausea and vomiting. J Anesth, 2017; 31:617-626. doi: 10.1007/s00540-017-2363-x.

3. Choi JB, Shim YH, Lee YW, Lee JS, Choi JR, Chang CH. Incidence and risk factors of postoperative nausea and vomiting in patients with fentanyl-based intravenous patient-controlled analgesia and single antiemetic prophylaxis. Yonsei Med J, 2014; 55:1430-1435. doi: 10.3349/ymj.2014.55.5.1430.

4. Lee YY, Kim KH, Yom YH. Predictive models for postoperative nausea and vomiting in patients using patient-controlled analgesia. J Int Med Res, 2007; 35:497-507. doi: 10.1177/147323000703500409.

5. Chen PP, Chui PT, Ma M, Gin T. A prospective survey of patients after cessation of patient-controlled analgesia. Anesth Analg, 2001; 92:224-227. doi: 10.1097/00000539-200101000-00043.

6. Food and Drug Administration. “Inapsine (droperidol) Dear Healthcare Professional Letter Dec 2001.”
7. White PF. Droperidol: a cost-effective antiemetic for over thirty years. Anesth Analg, 2002; 95:789-790. doi: 10.1097/00000539-200210000-00001.

8. Watcha MF. The cost-effective management of postoperative nausea and vomiting. Anesthesiology, 2000; 92:931-933. doi: 10.1097/00000542-200004000-00007.

9. Kuo YM, Tsou MY, Chang WK, Chan KH, Chang KY. To add or not to add? An empirical study on droperidol and intravenous patient-controlled analgesia. J Chin Med Assoc, 2012; 75:227-233. doi: 10.1016/j.jcma.2012.03.003.

10. Williams OA, Clarke FL, Harris RW, Smith P, Peacock JE. Addition of droperidol to patient-controlled analgesia: effect on nausea and vomiting. Anesth Analg, 1993; 48:881-884. doi: 10.1111/j.1365-2044.1993.tb07419.x.

11. Culebras X, Corpataux JB, Gaggero G, Tramèr MR. The anti-emetic efficacy of droperidol added to morphine patient-controlled analgesia: a randomized, controlled, multicenter dose-finding study. Anesth Analg, 2003; 97:816-821. doi: 10.1213/01.ane.0000078806.53162.89.

12. Klahsen AJ, O'Reilly D, McBride J, Ballantyne M, Parlow JL. Reduction of post-operative nausea and vomiting with the combination of morphine and droperidol in patient-controlled analgesia. Can J Anaesth, 1996; 43:1100-1107. doi: 10.1007/BF03011835.

13. Gan TJ, Alexander R, Fennelly M, Rubin AP. Comparison of different methods of administering droperidol in patient-controlled analgesia in the prevention of postoperative nausea and vomiting. Anesth Analg, 1995; 80:81-85. doi: 10.1097/00000539-199501000-00014.

14. McKenzie R, Tantisira B, Jackson D, Bach T, Riley T. Anti-emetic efficacy of a droperidol-morphine combination in patient-controlled analgesia. J Clin Anesth, 1995; 7:141-147. doi: 10.1016/0952-8180(94)00041-2.

15. Tsui SL, Irwin MG, Wong CM, Fung SK, Hui TW, Ng KF, Chan WS, O'Reagan AM. An audit of the safety of an acute pain service. Anaesthesia, 1997; 52:1042-1047. doi: https://doi.org/10.1111/j.1365-2044.1997.232-az0371.x.

16. Kissin I. Patient-controlled-analgesia analgesimetry and its problems. Anesth Analg, 2009; 108:1945-1949. doi: 10.1213/ane.0b013e3181a14a81.

17. Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth, 2012; 47:537-551. doi: https://doi.org/10.1007/BF03018945.

18. Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm, 2007; 64:1174-1186. doi: https://doi.org/10.2146/ajhp060505

19. Nuttall GA, Malone AM, Michels CA, Trudell LC, Renk TD, Marienau ME, Oliver WC, Ackerman MJ. Does low-dose droperidol increase the risk of polymorphic ventricular tachycardia or death in the surgical patient? Anesthesiology, 2013; 118:382-386. doi: 10.1097/ALN.0b013e31827dde8d.

20. White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology, 2005; 102:1101-1105. doi: 10.1097/00000542-200506000-00007.

21. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, Griffith S. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain, 2016; 17:131-157. doi: 10.1016/j.jpain.2015.12.008.

22. Kranke P1, Eberhart LH. Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting. Eur J Anaesthesiol, 2011; 28:758-765. doi: 10.1097/EJA.0b013e32834a4e1e.